Web Analytics

3 Latest Announced Rounds

  • $300,000,000
    Series B

    1 Investors

    Electric Power Generation
    Apr 3rd, 2026
  • $4,300,000
    Seed
    Medical and Diagnostic Laboratories
    Apr 3rd, 2026
  • $1,100,000
    Pre-Seed

    2 Investors

    Robotics Engineering
    Apr 3rd, 2026
$1,561.87M Raised in 34 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Ability Biologics

start up
Canada - Montreal, Quebec
  • 07/12/2023
  • Seed
  • $12,000,000

Our Mission:
Develop innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases.

The premier biotherapeutic targeting company

Our powerful AbiLeap™ discovery engine combines massively parallel, continuously learning AI with an extensive database of antigen-antibody interactions to generate fully human, IgG-based multispecific antibodies of exquisite selectivity and affinity. The antibodies respond to environmental signals within the cellular microenvironment, generating logic-gated therapeutics.

We are dedicated to developing the most potent and selective antibody therapeutics for areas of great unmet need.


Related People

Giles DayCo Founder

Giles Day United States - South San Francisco, California

N/A